Curriculum Vitae

Personal information

Farhad Tajarobi

Work experience

- Pharmaceutical assessor at Swedish Medical Products Agency (Feb. 2026 - present)
- Pharmacist and Pharmacy Quality Advisor, Carlanderska Hospital, Gothenburg/Sweden (Jan. 2024 - Jan 2026)
  - Filling perscribed medicines and patient advisory role on OTC products
  - Quality advisory and audit role in storage and handling of drug products in the different clinics within the hospital
- Associate Principle Scientist Oral Dosage Forms Formulation Design, AstraZeneca, Gothenburg, Sweden (May 2001 - May 2023)
  - Lead working groups and apply CMC product development technical knowledge in various early to late-stage clinical projects
  - Lead for the Formulation Design Global Technical Network, dealing with harmonizing ways of working within the company, surveilling new technologies, patient centric work streams and together with Procurement help to identify potential CRO/CMOs
  - Generate and review module 3 dossier to support regulatory submissions
- Bioanalytical chemist within Clinical Chemistry and Histology, Alingsås Hospital, Sweden (1994 - 1995)

Education and training

- PhD Pharmaceutical Technology, Chalmers University of Technology, Gothenburg, Sweden (2005 - 2010)
  The scope of the research was mainly the impact of physico-chemical properties of additives on the performance of Modified Release Formulations
- MSc Pharmacy, Uppsala University, Sweden (1995 - 2000)
- BSc Bioanalytical engineer within Clinical Chemistry and Histology, Borås Högskolan, Sweden (1992 - 1994)

Additional information

Publications

* Doctoral Thesis (2010, Chalmers University of Technology, ISBN 978-91-7385-458-0)) Dissolution and Release Behavior of Swellable Matrix Tablets; Influence of the solubility and dissolution rate enhancement of model substances

* F. Tajarobi, M. El-Sayed, B. D. Rege, J. E. Polli, H. Ghandehari. Transport of poly amidoamine dendrimers across Madin-Darby canine kidney cells, Int. J. Pharm. 2001, 215 (1-2), 263-267

* F. Tajarobi, S. Abrahmsén-Alami, A. S. Carlsson, A. Larsson. Simultaneous probing of swelling, erosion and dissolution by NMR-microimaging – Effect of solubility of additives on HPMC matrix tablets, Eur. J. Pharm. Sci. 2009, 37 (2), 89-97

* F. Tajarobi, S. Abrahmsén-Alami, M. Hansen, A. Larsson. The impact of dose and solubility of additives on the release from HPMC matrix tablets – identifying critical conditions, Pharm. Res. 2009, 26 (6)

* J. Unga, F. Tajarobi, O. Norder, G. Frenning, A. Larsson. Relating solubility of data of parabens in liquid PEG 400 to the behaviour of PEG 4000-parabens solid dispersion, Eur. J. Pharm. Biopharm. 2009, 73 (2)

* F. Tajarobi, S. Abrahmsén-Alami, A. Larsson. Dissolution rate enhancement of parabens in PEG solid dispersions and its influence of the release from hydrophilic matrix tablets, J. Pharm. Sci. 2011, 100 (1)

* F. Tajarobi, S. Abrahmsén-Alami, A. Larsson. The influence of crystallization inhibition of HPMC and HPMCAS on model substance dissolution and release in swellable matrix tablets. Eur. J. Pharm. Biopharm, 2011

* E. Kaunisto, F. Tajarobi, S. Abrahmsén-Alami, A. Larsson, B. Nilsson, A. Axelsson. Mechanistic modelling of drug release from a polymer matrix using magnetic resonance microimaging. Eur. J. Pharm. Sci, 2013

* Jain AK, Söderlind E, Viridén A, Schug B, Abrahamsson B, Knopke C3, Tajarobi F, Blume H, Anschütz M, Welinder A, Richardson S, Nagel S, Abrahmsén-Alami S, Weitschies W. The influence of hydroxypropyl methylcellulose (HPMC) molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets, JCR, 2014

* J. Heiman, F. Tajarobi, B. Gururajan, A. Juppo, S. Abrahmsén-Alami. Roller compaction of hydrophilic extended release tablets - Combined effects of processing variables and drug/matrix former particle size. AAPS PharmSciTech. 2014